Hap Trading, LLC Aprea Therapeutics, Inc. Call Options Transaction History

Hap Trading, LLC

$872 Billion
Q3 2024

Call Options

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q4 2022 Feb 14, 2023	BUY	$0.32 - $15.2 $1,344 - $63,840	4,200 Added 35.29%	16,100 $0
Q3 2022 Nov 14, 2022	BUY	$0.71 - $13.6 $710 - $13,600	1,000 Added 9.17%	11,900 $0
Q2 2022 Aug 12, 2022	SELL	$0.62 - $1.94 $11,594 - $36,278	-18,700 Reduced 63.18%	10,900 $1,000
Q1 2022 May 12, 2022	BUY	$1.59 - $3.16 $29,892 - $59,408	18,800 Added 174.07%	29,600 $5,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $5.58 $1,722 - $3,348	600 Added 5.88%	10,800 $4,000
Q3 2021 Nov 10, 2021	BUY	$3.43 - $5.63 $34,986 - $57,426	10,200 New	10,200 $9,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,625
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.